Biogen Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Viehbacher
- Full Time Employees
- 7,500
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 225 Binney Street Cambridge MA United States 02142
- IPO Date
- Sep 17, 1991
- CIK
- 0000875045
- Website
- biogen.com
- Similar Companies
- Business
- Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.
Company News
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Biogen Q3 Earnings Call Highlights
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Big Day for Econ Data, Hyperscaler Earnings
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
Biogen Swings to Loss, Logs Higher Sales
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Baron Health Care Fund: Q3 2026 New Positions And Exits
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Biogen Inc. $BIIB Shares Acquired by CWA Asset Management Group LLC
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)